Beximco Pharmaceuticals Ltd.

New product launches in 2016 (Updates as of 30th August)

Beximco Pharmaceuticals Ltd. (BPL), a leading pharmaceutical in Bangladesh having global footprint across 54 countries with its prescription medicine. Beximco pharma is a forefront in bringing new technology and generic has launched 12 products in 2016 across Cardiovascular, Endocrine Disorders, Antibiotics, Anti-viral, Respiratory and Ophthalmic portfolios. On 4 August 2016, Beximco Pharmaceuticals reached a new high became the first Bangladeshi Pharmaceutical Company to export Carvedilol to the United States of America.

Cardiovascular

Carvedilol Tablet

Carvedilol is a nonselective β-adrenergic blocking agent with α-blocking activity. It is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization. Carvedilol tablet is not approved for use in children under 18 years of age.
Carvedilol tablets are available as following strengths: 3.125 mg, 6.25 mg 12.5 mg and 25 mg tablets.

Now available in US Market

 

 

Anti-viral

Viracin®

Ribavirin 200mg capsule
Viracin® is the preparation of ribavirin 200 mg capsule. It is a nucleoside analogue indicated in combination with interferon alfa-2b (pegylated and nonpegylated) for the treatment of Chronic Hepatitis C (CHC) in patients 3 years of age or older with compensated liver disease. Ribavirin has teratogenic effect. Pregnancy should be avoided during and for 6 months after treatment in both female patients and the female partners of male patients treated with ribavirin.

Dakovir-C®

Daclatasvir 60 mg tablet
Dakovir-C® is the preparation of daclatasvir, a hepatitis C virus (HCV) NS5A inhibitor indicated for use with sofosbuvir with or without rivabirin for the treatment of chronic HCV genotype 1 or 3 infection. With the Dakovir-C® Beximco now offer full range of oral treatment for chronic HCV including Lesovir-C® tablet (ledipasvir 90mg / Sofosbuvir 400mg), Sofovir-C® tablet (Sofosbuvir 400mg) and viracin capsule (ribavirin 200mg)

 

Antibiotics

Tyclav®

(Amoxicillin / Clavulanate Potassium)
Powder for suspension: 100 ml (125 mg Amoxicillin /31.25 mg K Clavulanate Potassium / 5 ml)
BID suspension: 50 ml (400 mg Amoxicillin /57 mg Clavulanate Potassium /5ml)
Injection: 500 mg Amoxicillin /100 mg Clavulanate Potassium /vial; 1000 mg Amoxicillin / 200 mg Clavulanate Potassium /vial
Tyclav® (Clavulanate-potentiated Amoxicillin) is a broad spectrum bactericidal antibiotic effective against the commonly occurring bacterial pathogens in general practices and hospitals. The beta-lactamase inhibitory action of clavulanate extends the spectrum of amoxicillin Amoxicillin embrace a wider range of organisms, including many resistant ones to other beta-lactam antibiotics.

Turbocef®

Cefuroxime (as cefuroxime axetil) 125mg/5ml
Powder for suspension
Turbocef® oral suspension is a preparation of cefuroxime axetil. Cefuroxime axetil is a semisynthetic, broad-spectrum cephalosporin antibiotic for oral administration.
Turbocef® oral suspension is indicated for the treatment of mild to moderately severe infections caused by susceptible strains of the designated organisms.

 

Steroids

Bexipred®

Prednisolone 5mg, 10 mg & 20 mg Tablet
Prednisolone is a corticosteroid drug with predominant glucocorticoid & low mineralocorticoid activity. Bexipred® is indicated for:

  • as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation
  • for the treatment of certain endocrine conditions
  • for palliation of certain neoplastic conditions (Hematologic disorders: Idiopathic thrombocytopenic purpura in adults, secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, erythroblastopenia (RBC anemia), congenital (erythroid) hypoplastic anemia.

 

Endocrine & Diabetes

Diapro® 60 MR

Gliclazide 60 mg Modified Release Tablet
Diapro® is an oral blood glucose lowering drug of the sulfonylurea class. It is indicated to treat patients with type 2 diabetes mellitus. The primary mechanism of action of Diapro® is lowering of blood glucose by stimulating the release of insulin from functioning pancreatic beta cells. In addition, expancreatic effects may also play vital role in the activity of Diapro®. Administration of Diapro® can lead to increase sensitivity of peripheral tissues to insulin. Diapro® 60 modified release (MR) is given once daily

 

Respiratory

Azmasol® Respules

Salbutamol 2.5mg/3ml
Azmasol respules is a preparation of salbutamol comes as a solution (liquid) to inhale by mouth using nebulizer. Salbutamol is a selective β2-agonist providing short-acting (4-6 hour) bronchodilation with a fast onset (within 5 minutes) in reversible airways obstruction.
Azmasol® Respules are indicated for use in the routine management of chronic bronchospasm unresponsive to conventional therapy, and in the treatment of acute severe asthma. Azmasol® Respules having 3ml solution do not require further dilution and present easy to use as nebulization.

Iprasol® Respules

Ipratropium bromide 0.5mg and Salbutamol 2.5mg/3ml
Iprasol® Respules is a combination of the beta2-adrenergic bronchodilator, salbutamol sulphate, and the anticholinergic bronchodilator, ipratropium bromide.
Iprasol® Respules are indicated in patients with COPD on a regular aerosol bronchodilator, who continue to have evidence of bronchospasm and who require a second bronchodilator. As the content is 3ml Iprasol® Respules solution do not require further dilution.

Ipramid® Respules

Ipratropium bromide 0.5mg/2.5ml
Ipratropium Bromide respiratory solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.

Onriva® Bexicap

Indacaterol 150mcg powder for inhalation capsule
Onriva is a long-acting beta2-adrenergic agonist indicated for:
The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Do not swallow the capsule. The medicine is to be taken with Bexihaler® device as instructed in product insert.

 

Ophthalmic

Lacrison®

Loteprednol Etabonate ophthalmic suspension 0.5%
Lacrison® (loteprednol etabonate ophthalmic suspension) 0.5% contains a sterile, topical corticosteroid for ophthalmic use. Lacrison® is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.

Lacrison® T

loteprednol etabonate and tobramycin ophthalmic suspension, 0.5%/0.3%
Lacrison® T is a topical anti-infective and steroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.